Wire · regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The UK has suspended the use of Tavneos for new patients due to concerns over the drug’s benefit-risk profile and data reliability, with a six-month managed withdrawal period before full revocation of marketing authorization. Meanwhile, Amgen, which owns Tavneos in the US, awaits an FDA hearing as regulatory pressure mounts.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 2 Sep 2026 and 3 Sep 2026.
◆ ◆ The Wire takeaway
The UK’s suspension of new Tavneos patients signals tighter regulatory scrutiny on rare disease drugs with disputed data. You should review your drug safety evidence now or risk market access being abruptly closed where regulators grow wary.
◆ Coverage
2 sources · first reported 2 Sep 2026 · latest 3 Sep 2026
◆ Related on Wire
◆ Topics